ResearchApr 29, 2022
New risdiplam data shows long-term improvement in babies with Type 1 SMA

The latest data from the FIREFISH study of risdiplam was presented at the 14th European Paediatric Neurology Society (EPNS) Congress.
The latest data from the FIREFISH study of risdiplam was presented at the 14th European Paediatric Neurology Society (EPNS) Congress.
Biogen has provided us with a community statement to update our community on its work to support Ukrainian refugees, including those living with SMA.
We are happy to announce, that today the teaser of our OdySMA project goes live.
OdySMA is an initiative to reveal the “quest to access” of people living with SMA by mapping, visualising and centralising knowledge and data around access issues.
Latest risdiplam (Evrysdi) data updates, which were presented at the 2022 MDA Clinical and Scientific Conference on 13th - 16th March.